ArticleHemaSphere2026
Autologous stem cell transplantation versus consolidation chemotherapy as postremission treatment in newly diagnosed favorable- and intermediate-risk patients with AML: A comparative analysis of HOVON-SAKK-Nordic trials.
Article in HemaSphere, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
18 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
High-dose chemotherapy (CT), followed by autologous hematopoietic cell transplantation (auto-HCT) or consolidation CT, are postremission strategies for European LeukemiaNet 2022 (ELN2022) favorable- or intermediate-risk patients with acute myeloid leukemia (AML) in complete remission (CR) without measurable residual disease (MRD). We conducted a retrospective, nonrandomized analysis to compare the efficacy and safety of auto-HCT versus CT in newly diagnosed AML patients aged 18-65 years treated within two recent HOVON-SAKK-Nordic trials. From a total of 1005 patients with ELN2022 favorable- or intermediate-risk AML, 224 received busulfan/cyclophosphamide (Bu/Cy), followed by auto-HCT, and 199 received mitoxantrone/etoposide-based CT. The 5-year relapse-free survival (RFS) and overall survival (OS) were comparable between auto-HCT and CT (RFS: 60% vs. 56%, P = 0.70; OS: 72% vs. 71%, P = 0.76). In multivariable analysis, auto-HCT was not associated with a significant difference in RFS (HR 0.80, 95% CI 0.56-1.13, P = 0.20) or OS (HR 0.91, 95% CI 0.60-1.37, P = 0.64). Median time to platelet and neutrophil recovery was shorter with auto-HCT than CT (platelet: 42 vs. 57 days, neutrophil: 13 vs. 39 days). Subgroup analysis revealed that patients achieving CR after the second induction cycle or with baseline white blood cell counts >20 × 10
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.